Suppr超能文献

遗传性血小板减少性紫癜的临床诊断与治疗:附5例报告及文献复习

[Clinical diagnosis and treatment of hereditary thrombocytopenia and purpura: a report of five cases and literature review].

作者信息

Lyu X P, Yin J, Kong D Q, Tian H, Li Y, Qyu Q, Su J, Cao L J, Bai X, Yu Z Q, Wang Z Y, Wu D P, Ruan C G

机构信息

Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Disease, NHC Key Laboratory of Thrombosis and Hemostasis, The First Affiliated Hospital of Soochow University, Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215006, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2023 Jan 14;44(1):43-47. doi: 10.3760/cma.j.issn.0253-2727.2023.01.008.

Abstract

To report the clinical manifestations and laboratory features of five patients with congenital thrombotic thrombocytopenic purpura (cTTP) and explore its standardized clinical diagnosis and treatment along with a review of literature. Clinical data of patients, such as age of onset, disease manifestation, personal history, family history, and misdiagnosed disease, were collected. Treatment outcomes, therapeutic effects of plasma infusion, and organ function evaluation were observed. The relationship among the clinical manifestations, treatment outcomes, and ADAMTS13 gene mutation of patients with cTTP was analyzed. Additionally, detection of ADAMTS13 activity and analysis of ADAMTS13 gene mutation were explored. The age of onset of cTTP was either in childhood or adulthood except in one case, which was at the age of 1. The primary manifestations were obvious thrombocytopenia, anemia, and different degrees of nervous system involvement. Most of the patients were initially suspected of having immune thrombocytopenia. Acute cTTP was induced by pregnancy and infection in two and one case, respectively. ADAMTS13 gene mutation was detected in all cases, and there was an inherent relationship between the mutation site, clinical manifestations, and degree of organ injury. Therapeutic or prophylactic plasma transfusion was effective for treating cTTP. The clinical manifestations of cTTP vary among individuals, resulting in frequent misdiagnosis that delays treatment. ADAMTS13 activity detection in plasma and ADAMTS13 gene mutation analysis are important bases to diagnose cTTP. Prophylactic plasma transfusion is vital to prevent the onset of the disease.

摘要

报告5例先天性血栓性血小板减少性紫癜(cTTP)患者的临床表现和实验室特征,探讨其规范化临床诊断与治疗方法,并进行文献复习。收集患者的临床资料,如发病年龄、疾病表现、个人史、家族史及误诊疾病等。观察治疗结果、血浆输注的治疗效果及器官功能评估情况。分析cTTP患者的临床表现、治疗结果与ADAMTS13基因突变之间的关系。此外,探讨ADAMTS13活性检测及ADAMTS13基因突变分析。cTTP的发病年龄除1例为1岁外,其余均在儿童期或成年期。主要表现为明显的血小板减少、贫血及不同程度的神经系统受累。多数患者最初被怀疑患有免疫性血小板减少症。急性cTTP分别由妊娠和感染诱发,各2例和1例。所有病例均检测到ADAMTS13基因突变,且突变位点、临床表现及器官损伤程度之间存在内在联系。治疗性或预防性血浆输注对治疗cTTP有效。cTTP的临床表现因人而异,导致误诊频繁,延误治疗。血浆ADAMTS13活性检测及ADAMTS13基因突变分析是诊断cTTP的重要依据。预防性血浆输注对预防该病发作至关重要。

相似文献

1
[Clinical diagnosis and treatment of hereditary thrombocytopenia and purpura: a report of five cases and literature review].
Zhonghua Xue Ye Xue Za Zhi. 2023 Jan 14;44(1):43-47. doi: 10.3760/cma.j.issn.0253-2727.2023.01.008.
3
First reported case of congenital thrombotic thrombocytopenic purpura in Taiwan with novel mutation of ADAMTS13 gene.
Int J Hematol. 2021 May;113(5):760-764. doi: 10.1007/s12185-020-03068-5. Epub 2021 Jan 2.
4
Success and limitations of plasma treatment in pregnant women with congenital thrombotic thrombocytopenic purpura.
J Thromb Haemost. 2020 Nov;18(11):2929-2941. doi: 10.1111/jth.15064. Epub 2020 Oct 15.
5
8
Toward gene therapy for congenital thrombotic thrombocytopenic purpura.
J Thromb Haemost. 2023 May;21(5):1090-1099. doi: 10.1016/j.jtha.2022.12.018. Epub 2022 Dec 27.
10
Characterization and treatment of congenital thrombotic thrombocytopenic purpura.
Blood. 2019 Apr 11;133(15):1644-1651. doi: 10.1182/blood-2018-11-884700. Epub 2019 Feb 15.

本文引用的文献

1
Morbidities and mortality in patients with hereditary thrombotic thrombocytopenic purpura.
Blood Adv. 2022 Feb 8;6(3):750-759. doi: 10.1182/bloodadvances.2021005760.
2
Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis.
Blood. 2022 Jan 27;139(4):597-607. doi: 10.1182/blood.2021011776.
4
Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura.
Blood. 2021 Jun 24;137(25):3563-3575. doi: 10.1182/blood.2020009801.
5
Redefining outcomes in immune TTP: an international working group consensus report.
Blood. 2021 Apr 8;137(14):1855-1861. doi: 10.1182/blood.2020009150.
6
Success and limitations of plasma treatment in pregnant women with congenital thrombotic thrombocytopenic purpura.
J Thromb Haemost. 2020 Nov;18(11):2929-2941. doi: 10.1111/jth.15064. Epub 2020 Oct 15.
7
Real-world experience with caplacizumab in the management of acute TTP.
Blood. 2021 Apr 1;137(13):1731-1740. doi: 10.1182/blood.2020007599.
8
Clinical Features and Gene Mutation Analysis of Congenital Thrombotic Thrombocytopenic Purpura in Neonates.
Front Pediatr. 2020 Sep 22;8:546248. doi: 10.3389/fped.2020.546248. eCollection 2020.
9
ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura.
J Thromb Haemost. 2020 Oct;18(10):2486-2495. doi: 10.1111/jth.15006. Epub 2020 Sep 11.
10
ISTH guidelines for treatment of thrombotic thrombocytopenic purpura.
J Thromb Haemost. 2020 Oct;18(10):2496-2502. doi: 10.1111/jth.15010. Epub 2020 Sep 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验